Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

omalizumab

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of omalizumab

62 trials tracked of omalizumab: 40 in phase 3 or 4 and 17 with published results. The most-cited published study has 291 citations.

62Trials tracked

40Phase 3 & 4

0Recruiting

17With published results

Phase distribution

Phase 4 21 Phase 3 19 Phase 2 20 Phase 1 1 Other / NA 1

Phase 3 Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants Completed · 291 cited
Phase 3 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed · 128 cited
Phase 3 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Completed · 96 cited
Phase 3 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Completed · 96 cited
Phase 4 Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization Completed · 63 cited
Phase 3 A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Completed · 62 cited

Show 44 more trials

Phase 3 A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Completed · 62 cited
Phase 3 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed · 38 cited
Phase 4 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Completed · 36 cited
Phase 4 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed · 35 cited
Phase 3 Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria Completed · 29 cited
Phase 4 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Completed · 27 cited
Phase 4 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed · 21 cited
Phase 3 An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Completed · 21 cited
Phase 4 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) Completed · 20 cited
Phase 4 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Completed · 15 cited
Phase 4 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Completed · 4 cited
Phase 4 Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils Completed
Phase 4 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed
Phase 4 Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) Completed
Phase 4 Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma Completed
Phase 4 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed
Phase 4 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed
Phase 4 A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy Completed
Phase 4 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations Completed
Phase 4 Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed
Phase 4 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed
Phase 4 Inner-City Anti-IgE Therapy for Asthma Completed
Phase 4 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed
Phase 4 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed
Phase 3 Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients Completed
Phase 3 Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients Completed
Phase 3 A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Completed
Phase 3 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Completed
Phase 3 Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma Completed
Phase 3 Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. Completed
Phase 3 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy Completed
Phase 3 Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis Completed
Phase 3 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed
Phase 3 Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma Completed
Phase 2 Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria Completed
Phase 2 The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge Completed
Phase 2 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Completed
Phase 2 Multi OIT to Test Immune Markers After Minimum Maintenance Dose Completed
Phase 2 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Completed
Phase 2 Cold Urticaria Treatment With Xolair Completed
Phase 2 Omalizumab in the Treatment of Peanut Allergy Completed
Phase 2 Multi Immunotherapy to Test Tolerance and Xolair Completed
Phase 2 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed
Phase 2 A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) Completed

Showing the 50 most-cited and recently-updated of 62 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.